Drugs / Dimephosphon
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT07167550 | Sep 2025 → Jan 2026 overdue | ischemic stroke | Tatchempharmpreparaty, JSC | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Dimephosphon | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07167550 ↗ |
| Route | Intravenous | “administered as intravenous infusion” NCT07167550 ↗ |